Protein Kinase Inhibitors

• 

  Subject Areas on Research

  • A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. 
  • A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates. 
  • A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. 
  • A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. 
  • A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. 
  • A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. 
  • A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 
  • A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. 
  • A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. 
  • A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. 
  • A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. 
  • A beta-adrenergic receptor kinase-like enzyme is involved in olfactory signal termination. 
  • A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. 
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. 
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. 
  • A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. 
  • A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. 
  • A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1. 
  • A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. 
  • A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). 
  • A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). 
  • A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. 
  • A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). 
  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. 
  • A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. 
  • A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. 
  • A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. 
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 
  • ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. 
  • AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. 
  • Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages. 
  • Abl family kinases regulate endothelial barrier function in vitro and in mice. 
  • Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. 
  • Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs. 
  • Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. 
  • Adjuvant chemotherapy for non-small cell lung cancer. 
  • Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014. 
  • Advanced Melanoma: Resistance Mechanisms to Current Therapies. 
  • Akt-dependent and -independent mechanisms of mTOR regulation in cancer. 
  • Ameliorating reperfusion injury in STEMI: dead or alive? 
  • An explant technique for high-resolution imaging and manipulation of mycobacterial granulomas. 
  • An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. 
  • An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. 
  • Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. 
  • Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. 
  • Anti-epidermal growth factor receptor therapy for glioblastoma in adults. 
  • Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. 
  • Antiseizure effects of TrkB kinase inhibition. 
  • Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). 
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. 
  • Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. 
  • Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. 
  • Axokinin phosphorylation by cAMP-dependent protein kinase is sufficient for activation of sperm flagellar motility. 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • BRAF in melanoma: current strategies and future directions. 
  • BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. 
  • Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. 
  • Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. 
  • Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. 
  • Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: a comparative study of 67 cases. 
  • Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice. 
  • CDK12 Activity-Dependent Phosphorylation Events in Human Cells. 
  • CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. 
  • CDK4/6 inhibitors in breast cancer. 
  • CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. 
  • CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. 
  • CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL). 
  • CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter? 
  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
  • Ca(2+)-dependent interaction of recoverin with rhodopsin kinase. 
  • CaMKII is essential for the proasthmatic effects of oxidation. 
  • Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. 
  • Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. 
  • Cabozantinib in genitourinary malignancies. 
  • Calcium/calmodulin-dependent protein kinase II. Characterization of distinct calmodulin binding and inhibitory domains. 
  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? 
  • Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. 
  • Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. 
  • Cardiometabolic Consequences of Targeted Anticancer Therapies. 
  • Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. 
  • Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. 
  • Cellular senescence: from anti-cancer weapon to anti-aging target. 
  • Challenges and Emerging Opportunities for Targeting mTOR in Cancer. 
  • Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. 
  • Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. 
  • Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing. 
  • Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. 
  • Chemical interrogation of the malaria kinome. 
  • Chemoprevention of pancreatic cancer: ready for the clinic? 
  • Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP. 
  • Chronic Myelogenous Leukemia, Version 1.2014. 
  • Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. 
  • Chronic myelogenous leukemia, version 1.2015. 
  • Chronic myelogenous leukemia. 
  • Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. 
  • Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. 
  • Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy. 
  • Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. 
  • Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 
  • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. 
  • Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. 
  • Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. 
  • Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. 
  • Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor. 
  • Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. 
  • Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. 
  • Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma. 
  • Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. 
  • Commentary: New players in epidermal growth factor receptor tyrosine kinase inhibitor resistance. 
  • Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. 
  • Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. 
  • Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. 
  • Control of simian virus 40 DNA replication by the HeLa cell nuclear kinase casein kinase I. 
  • Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. 
  • Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. 
  • Covalent labelling of ligand binding sites of human placental S-adenosylhomocysteine hydrolase with 8-azido derivatives of adenosine and cyclic AMP. 
  • Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. 
  • Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells. 
  • Current and Emerging Treatment for Diabetic Macular Edema. 
  • Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors 
  • Cyclic adenosine 3':5'-monophosphate-dependent protein kinase. 
  • DEK is required for homologous recombination repair of DNA breaks. 
  • DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study. 
  • Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia. 
  • De Novo Fragment Design for Drug Discovery and Chemical Biology. 
  • Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. 
  • Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. 
  • Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS. 
  • Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. 
  • Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. 
  • Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy. 
  • Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. 
  • Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. 
  • Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase. 
  • Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. 
  • Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers. 
  • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 
  • Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. 
  • Disruption of the gene encoding the mitogen-regulated translational modulator PHAS-I in mice. 
  • Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control. 
  • Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. 
  • Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. 
  • Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. 
  • Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. 
  • Duration of Trastuzumab. In matters of the heart, one size may not fit all? 
  • Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells. 
  • E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells. 
  • EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. 
  • EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. 
  • EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. 
  • ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. 
  • Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance. 
  • Editorial: Infections of the immunocompromised host: a musing on the changing times. 
  • Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. 
  • Effects of Selonsertib in Patients with Diabetic Kidney Disease. 
  • Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. 
  • Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. 
  • Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. 
  • Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis. 
  • Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. 
  • Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. 
  • Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. 
  • Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. 
  • Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. 
  • Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. 
  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. 
  • Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 
  • Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. 
  • Epidermal growth factor regulates hematopoietic regeneration after radiation injury. 
  • Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. 
  • Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 
  • Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition. 
  • Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. 
  • Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. 
  • Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. 
  • FSH stimulation of protein kinase inhibitor: regulation of cellular metabolism. 
  • Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib. 
  • First- and third-generation epidermal growth factor receptor inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatological reactions. 
  • Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. 
  • G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Gefitinib for refractory advanced non-small-cell lung cancer. 
  • Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain. 
  • Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. 
  • Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors. 
  • Glioblastoma multiforme and the epidermal growth factor receptor. 
  • HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. 
  • Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. 
  • Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions. 
  • Heart rate decrease during crizotinib treatment and potential correlation to clinical response. 
  • Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. 
  • Heritable resistance to tyrosine kinase inhibitors. 
  • Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. 
  • Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. 
  • Hyposmotically activated chloride channels in cultured rabbit non-pigmented ciliary epithelial cells. 
  • IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. 
  • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. 
  • Identification of 3-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-ones as isoform-selective PKC-zeta inhibitors and potential therapeutics for psychostimulant abuse. 
  • Identification of a small molecule that stimulates human β-cell proliferation and insulin secretion, and protects against cytotoxic stress in rat insulinoma cells. 
  • Identification, partial purification, and characterization of a novel phospholipid-dependent and fatty acid-activated protein kinase from human platelets. 
  • Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. 
  • Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. 
  • Immediate and long-term consequences of vascular toxicity during zebrafish development. 
  • Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. 
  • In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors. 
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. 
  • Induction of miR-132 and miR-212 Expression by Glucagon-Like Peptide 1 (GLP-1) in Rodent and Human Pancreatic β-Cells. 
  • Inflammatory myofibroblastic tumor: A multi-institutional study from the Pediatric Surgical Oncology Research Collaborative. 
  • Inhibiting Glycogen Synthase Kinase-3 Mitigates the Hematopoietic Acute Radiation Syndrome in a Sex- and Strain-dependent Manner in Mice. 
  • Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice. 
  • Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. 
  • Inhibition of beta-adrenergic receptor kinase prevents rapid homologous desensitization of beta 2-adrenergic receptors. 
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 
  • Inhibition of p38 Mitogen-Activated Protein Kinase Enhances the Apoptosis Induced by Oxidized Low-Density Lipoprotein in Endothelial Progenitor Cells. 
  • Inhibition of spinal p38 MAPK prevents articular neutrophil infiltration in experimental arthritis via sympathetic activation. 
  • Inhibition of the beta-adrenergic receptor kinase by polyanions. 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. 
  • Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. 
  • Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. 
  • Initial testing of dasatinib by the pediatric preclinical testing program. 
  • Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. 
  • Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). 
  • Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. 
  • Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. 
  • Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. 
  • Intracellular mechanisms of gonadotropin-stimulated gene expression in granulosa cells. 
  • Intracellular mediators of insulin action. 
  • Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'. 
  • Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. 
  • Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease. 
  • Isolation and characterization of a protein from rat testis which inhibits cyclic AMP-dependent protein kinase and phosdiesterase. 
  • Isolation and regulation of the protein kinase inhibitor and the calcium-dependent cyclic nucleotide phosphodiesterase regulator in the Sertoli cell-enriched testis. 
  • JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. 
  • Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. 
  • Kalirin promotes neointimal hyperplasia by activating Rac in smooth muscle cells. 
  • Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. 
  • LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease. 
  • LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 
  • Larotrectinib: A Targeted Therapy for Solid Tumors. 
  • Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. 
  • Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. 
  • Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. 
  • Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. 
  • MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. 
  • MEK inhibition in the treatment of advanced melanoma. 
  • MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. 
  • MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. 
  • MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease. 
  • MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. 
  • Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. 
  • Matrix stiffness regulation of integrin-mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells. 
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. 
  • Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 
  • Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. 
  • MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. 
  • Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review. 
  • Mitogen-activated protein kinases in heart development and diseases. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modulation of thromboxane receptor activation in rat glomerular mesangial cells. 
  • Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. 
  • Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. 
  • Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. 
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 
  • N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. 
  • NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. 
  • NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. 
  • NCCN Task Force Report: mTOR inhibition in solid tumors. 
  • NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. 
  • NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. 
  • Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. 
  • Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study. 
  • Neuro-ophthalmic side effects of molecularly targeted cancer drugs. 
  • New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. 
  • Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. 
  • Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway. 
  • Nuclear receptor LXRalpha is involved in cAMP-mediated human renin gene expression. 
  • Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 
  • Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. 
  • Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. 
  • Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. 
  • Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. 
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. 
  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience. 
  • PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. 
  • PP1-mediated dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1 and PP1 phosphorylation. 
  • PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. 
  • PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. 
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. 
  • Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. 
  • Parameters for lithium treatment are critical in its enhancement of fracture-healing in rodents. 
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. 
  • Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. 
  • Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. 
  • Patients' perspectives on the definition of cure in chronic myeloid leukemia. 
  • Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report. 
  • Perifosine: update on a novel Akt inhibitor. 
  • Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. 
  • Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. 
  • Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. 
  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. 
  • Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. 
  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 
  • Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. 
  • Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. 
  • Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. 
  • Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. 
  • Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. 
  • Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. 
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. 
  • Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. 
  • Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. 
  • Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. 
  • Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. 
  • Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. 
  • Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. 
  • Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 
  • Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. 
  • Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. 
  • Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis. 
  • Phrenic long-term facilitation requires PKCθ activity within phrenic motor neurons. 
  • Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. 
  • Polyploidy and Mitotic Cell Death Are Two Distinct HIV-1 Vpr-Driven Outcomes in Renal Tubule Epithelial Cells. 
  • Post-transcriptional inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase by Gö6976 in murine microglia. 
  • Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer. 
  • Preclinical efficacy of MEK inhibition in Nras-mutant AML. 
  • Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. 
  • Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. 
  • Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. 
  • Progress in breast cancer-can we do better? 
  • Protein inhibitor of cAMP-dependent protein kinase: production and characterization of antibodies and intracellular localization. 
  • Protein kinase C signaling during T cell activation induces the endoplasmic reticulum stress response. 
  • Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. 
  • RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. 
  • RIP3 induces apoptosis independent of pronecrotic kinase activity. 
  • Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone? 
  • Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. 
  • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 
  • Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. 
  • Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. 
  • Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. 
  • Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. 
  • Receptor-associated protein binding blocks ubiquitinylation of the low density lipoprotein receptor-related protein. 
  • Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). 
  • Recoverin undergoes light-dependent intracellular translocation in rod photoreceptors. 
  • Regression of Epileptogenesis by Inhibiting Tropomyosin Kinase B Signaling following a Seizure. 
  • Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. 
  • Regulation of cofilin phosphorylation in glomerular podocytes by testis specific kinase 1 (TESK1). 
  • Regulation of intrasteric inhibition of the multifunctional calcium/calmodulin-dependent protein kinase. 
  • Regulation of protein kinase inhibitor by follicle-stimulating hormone in Sertoli cells in vitro. 
  • Regulation of the testis sertoli cell by follicle stimulating hormone. 
  • Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. 
  • Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss. 
  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. 
  • Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. 
  • Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. 
  • RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. 
  • Role of ABL family kinases in cancer: from leukaemia to solid tumours. 
  • Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. 
  • SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. 
  • SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. 
  • STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. 
  • SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. 
  • Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. 
  • Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms. 
  • Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. 
  • Sites in the third intracellular loop of the alpha 2A-adrenergic receptor confer short term agonist-promoted desensitization. Evidence for a receptor kinase-mediated mechanism. 
  • Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. 
  • Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Specific inhibition of protein kinase A in granulosa cells abolishes gonadotropin regulation of the proopiomelanocortin promoter. 
  • Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. 
  • Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. 
  • Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. 
  • Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. 
  • Sunitinib in patients with metastatic renal cell carcinoma. 
  • Surgical options for advanced/metastatic gastrointestinal stromal tumors. 
  • Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. 
  • Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. 
  • Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase. 
  • Synthetic peptides of the hamster beta 2-adrenoceptor as substrates and inhibitors of the beta-adrenoceptor kinase. 
  • Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. 
  • TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. 
  • Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. 
  • Targeted disruption of Mapk14 (p38MAPKalpha) in granulosa cells and cumulus cells causes cell-specific changes in gene expression profiles that rescue COC expansion and maintain fertility. 
  • Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies. 
  • Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma. 
  • Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. 
  • Targeting Pim Kinases and DAPK3 to Control Hypertension. 
  • Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. 
  • Targeting slow-proliferating ovarian cancer cells. 
  • Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. 
  • Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. 
  • Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. 
  • The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. 
  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. 
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. 
  • The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. 
  • The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease. 
  • The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML). 
  • The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition. 
  • The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. 
  • The Role of Angiogenesis in Hepatocellular Carcinoma. 
  • The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. 
  • The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 
  • The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. 
  • The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. 
  • The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. 
  • The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. 
  • The protein tyrosine kinase inhibitor, genistein, decreases excitability of nociceptive neurons. 
  • The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. 
  • The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. 
  • The role of tuberous sclerosis complex 1 in regulating innate immunity. 
  • The roles of 14-3-3 proteins in signal transduction. 
  • The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. 
  • Therapeutic Effect of Targeting Branched-Chain Amino Acid Catabolic Flux in Pressure-Overload Induced Heart Failure. 
  • Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies. 
  • Thrombospondin-1 mediates Rho-kinase inhibitor-induced increase in outflow-facility. 
  • Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. 
  • Trametinib (GSK1120212) in the treatment of melanoma. 
  • Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. 
  • Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. 
  • Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. 
  • Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. 
  • TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. 
  • Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. 
  • Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. 
  • Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy. 
  • Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients. 
  • Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. 
  • Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. 
  • Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma. 
  • Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. 
  • VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. 
  • Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). 
  • Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. 
  • WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. 
  • WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop. 
  • Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. 
  • Wound contraction is attenuated by fasudil inhibition of Rho-associated kinase. 
  • Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. 
  • X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Cell Biology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society
  • Zhong, Xiaoping, Professor of Pediatrics, Integrative Immunobiology